T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Follow-Up Questions
T2 Biosystems Inc의 CEO는 누구입니까?
Mr. John Sperzel은 2020부터 회사에 합류한 T2 Biosystems Inc의 Chairman of the Board입니다.
TTOO 주식의 가격 성능은 어떻습니까?
TTOO의 현재 가격은 $0.0035이며, 전 거래일에 decreased 0% 하였습니다.
T2 Biosystems Inc의 주요 사업 주제나 업종은 무엇입니까?
T2 Biosystems Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
T2 Biosystems Inc의 시가총액은 얼마입니까?
T2 Biosystems Inc의 현재 시가총액은 $98175입니다
T2 Biosystems Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 T2 Biosystems Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다
